Story · Medicine & Biotech

Lilly beats Novo to China with an oral GLP-1 for obesity

3 outlets · first reported by Pharmaphorum on · latest · 53 hours of coverage · 3 countries

Lilly beats Novo to China with an oral GLP-1 for obesity Phil.Taylor Thu, 12/11/2026 - 09:28 (Pharmaphorum)

Coverage, in order

  1. first Pharmaphorum UK indie
    Lilly beats Novo to China with an oral GLP-1 for obesity

    Lilly beats Novo to China with an oral GLP-1 for obesity Phil.Taylor Thu, 12/11/2026 - 09:28

  2. Medical Xpress indie n=630
    China approves first oral GLP-1 weight-loss pill

    China has approved its first orally administered GLP-1 weight-loss drug, permitting Eli Lilly to sell its orforglipron pill in a market where 630 million adults could be overweight or obese by 2050.

  3. Medical Dialogues India obscure
    Eli Lilly's Oral Obesity Drug Orforglipron Gets China Approval, Challenging Novo's Wegovy

    Shanghai : Eli Lilly on Thursday became the first drugmaker to win approval in China for a GLP-1 weight-loss pill, giving it an early advantage over Danish rival Novo Nordisk in the world's second-largest pharmaceutical market. Lilly's orforglipron pill — marketed ​as Foundayo in the US — will…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.